Status:
NOT_YET_RECRUITING
Botox Versus Tacrolimus in Psoriasis Vulgaris
Lead Sponsor:
Assiut University
Conditions:
Psoriasis Vulgaris
Eligibility:
All Genders
18-60 years
Phase:
PHASE4
Brief Summary
Psoriasis is a systemic chronic relapsing immune-mediated disease which often requires a long-term therapy. Psoriasis occurs in around 2-3% of the total global population. In Egypt, the prevalence of ...
Detailed Description
Neurogenic inflammation has been suggested as an etiopathogenic factor of psoriasis. Previous reports revealed an increased concentration of nerve fibers as well as a high level of neuropeptides of cu...
Eligibility Criteria
Inclusion
- Patients with clinical diagnosis of mild to moderate psoriasis vulgaris
- Patients who stopped any systemic therapy or phototherapy for at least 3 months and topical therapy for at least 4 weeks prior to enrollment.
Exclusion
- • Psoriasis vulgaris involving \> 10% of the body surface area, pustular or erythrodermic psoriasis.
- Patients with neuromuscular disease or history of epilepsy.
- Pregnant or lactating females.
- Patients with any current dermatological disease.
- Patients with any current systemic disease.
Key Trial Info
Start Date :
June 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2026
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06203470
Start Date
June 1 2024
End Date
October 1 2026
Last Update
June 12 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.